Lunai Bioworks (LNAI) Equity Average (2011 - 2026)

Lunai Bioworks' Equity Average history runs 16 years deep, the most recent figure standing at -$11.6 million for Q1 2026.

• In Q1 2026, Equity Average fell 113.55% year-over-year to -$11.6 million; the TTM figure through Mar 2026 stood at -$11.6 million (down 113.55% YoY), while the FY2025 annual figure was $55.3 million, down 38.02% from the prior year.
• Equity Average was -$11.6 million for Q1 2026 at Lunai Bioworks, up from -$13.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $163.4 million in Q1 2022 to a low of -$17.2 million in Q3 2025.
• Historically, Equity Average has averaged $67.0 million across 5 years, with a median of $68.6 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Equity Average soared 146.72% in 2024, then slumped 114.95% in 2025.
• A 5-year view of Equity Average shows it stood at $68.6 million in 2022, then sank by 34.16% to $45.2 million in 2023, then soared by 99.41% to $90.1 million in 2024, then tumbled by 114.76% to -$13.3 million in 2025, then climbed by 13.12% to -$11.6 million in 2026.
• The last three Equity Average figures came in at -$11.6 million (Q1 2026), -$13.3 million (Q4 2025), and -$17.2 million (Q3 2025), per Business Quant data.